clinical trial – Page 6

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

By MedXY 08/02/2025

Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.

Clinical Updates news Respiratory Specialties

Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

By MedXY 08/02/2025

Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.

Clinical Updates news Oncology Specialties

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY 08/01/2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Clinical Updates news OB/GYN & Women's Health Pediatrics Specialties

Trimethoprim–Sulfamethoxazole in Pregnancy: No Impact on Birth Weight in a Zimbabwean RCT

By MedXY 08/01/2025

A large randomized trial in Zimbabwe found that trimethoprim–sulfamethoxazole prophylaxis during pregnancy did not significantly increase birth weight or reduce adverse outcomes.

Clinical Updates Hematology-Oncology news Specialties

Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results

By MedXY 08/01/2025

A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.

news Oncology Specialties

Zongertinib: A Promising Oral Targeted Therapy for Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

By MedXY 08/01/2025

Zongertinib shows high response rates and manageable toxicity in HER2-mutant NSCLC after prior treatments, offering a new oral therapy option.

Clinical Updates Gastroenterology Medical News Specialties

Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results and Clinical Implications

By MedXY 08/01/2025

A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.

Clinical Updates Neurology news Specialties

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

By MedXY 07/31/2025

The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant benefit.

Clinical Updates news

Intra-arterial Tenecteplase After Thrombectomy for Acute Stroke: Interpreting the ANGEL-TNK Randomized Clinical Trial

By MedXY 07/31/2025

Clinical Updates Orthopedics Specialties

High Tibial Osteotomy May Slow Knee Osteoarthritis Progression in Bowlegged Patients: Clinical Insights from a Randomized Trial

By MedXY 07/30/2025

High tibial osteotomy (HTO) slows cartilage loss and improves pain and function in bowlegged patients with medial knee osteoarthritis compared to nonsurgical management, according to a new randomized trial.

Clinical Updates Dermatology news Specialties

FDA Fast-Tracks Rezpegaldesleukin for Severe Alopecia Areata: Promise for a Challenging Disease

By MedXY 07/30/2025

The FDA has granted Fast Track status to rezpegaldesleukin (REZPEG), a novel biologic targeting regulatory T cells, for severe-to-very severe alopecia areata in patients aged ≥12 years. Phase 2b trial results are anticipated in December 2025.

news OB/GYN & Women's Health Specialties

DM199 Shows Promise as a Potential Treatment for Preeclampsia

By MedXY 07/29/2025

DM199 has demonstrated safety and efficacy in reducing blood pressure among preeclampsia patients during a Phase 2 trial, offering hope for improved maternal and fetal outcomes.